Literature DB >> 8454062

Purification and characterization of a 90 kDa protein released from human tumors and tumor cell lines.

S Iacobelli1, I Bucci, M D'Egidio, C Giuliani, C Natoli, N Tinari, M Rubistein, J Schlessinger.   

Abstract

A novel tumor-associated protein, termed 90K, and recognized by mAb SP-2 was purified from serum of breast cancer patients, ovarian cancer ascitic fluid and conditioned medium of human breast cancer cells. In these three sources, native 90K is present as a high molecular weight complex that was dissociated by SDS-PAGE into a major band of approximately 90,000 Da. On the basis of electrophoretic mobility, buoyant density value, amino acid composition, and immunoreactivity, the 90K from the different sources appeared to be identical. NH2-terminal amino acid sequence revealed no homology to known protein.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8454062     DOI: 10.1016/0014-5793(93)80037-u

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  13 in total

1.  Galectin-3 Binding Protein Secreted by Breast Cancer Cells Inhibits Monocyte-Derived Fibrocyte Differentiation.

Authors:  Michael J V White; David Roife; Richard H Gomer
Journal:  J Immunol       Date:  2015-07-01       Impact factor: 5.422

2.  Cyclophilin C-associated protein: a normal secreted glycoprotein that down-modulates endotoxin and proinflammatory responses in vivo.

Authors:  M Trahey; I L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

3.  Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds beta1 integrins, collagens and fibronectin.

Authors:  T Sasaki; C Brakebusch; J Engel; R Timpl
Journal:  EMBO J       Date:  1998-03-16       Impact factor: 11.598

4.  Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs.

Authors:  Heinz Läubli; Frederico Alisson-Silva; Michal A Stanczak; Shoib S Siddiqui; Liwen Deng; Andrea Verhagen; Nissi Varki; Ajit Varki
Journal:  J Biol Chem       Date:  2014-10-15       Impact factor: 5.157

5.  Identification of Mac-2-binding protein as a putative marker of neuroendocrine tumors from the analysis of cell line secretomes.

Authors:  Rajaventhan Srirajaskanthan; Martyn E Caplin; Mark G Waugh; Jennifer Watkins; Tim Meyer; J Justin Hsuan; Nicholas J Beaumont
Journal:  Mol Cell Proteomics       Date:  2009-12-17       Impact factor: 5.911

6.  Mac-2 binding protein is a novel E-selectin ligand expressed by breast cancer cells.

Authors:  Venktesh S Shirure; Nathan M Reynolds; Monica M Burdick
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

7.  Different protein composition and functional properties of adeno-associated virus-6 vector manufactured from the culture medium and cell lysates.

Authors:  Jerome Denard; Christine Jenny; Véronique Blouin; Philippe Moullier; Fedor Svinartchouk
Journal:  Mol Ther Methods Clin Dev       Date:  2014-07-30       Impact factor: 6.698

Review 8.  A review of studies of the proteomes of circulating microparticles: key roles for galectin-3-binding protein-expressing microparticles in vascular diseases and systemic lupus erythematosus.

Authors:  Christoffer T Nielsen; Ole Østergaard; Niclas S Rasmussen; Søren Jacobsen; Niels H H Heegaard
Journal:  Clin Proteomics       Date:  2017-04-08       Impact factor: 3.988

9.  Cyclophilin C-associated protein (CyCAP) knock-out mice spontaneously develop colonic mucosal hyperplasia and exaggerated tumorigenesis after treatment with carcinogen azoxymethane.

Authors:  Emina Emilia Torlakovic; Vicki Keeler; Chang Wang; Hyun J Lim; Leslie Ann Lining; Suzanne Laferté
Journal:  BMC Cancer       Date:  2009-07-24       Impact factor: 4.430

10.  Prognostic value of a novel circulating serum 90K antigen in breast cancer.

Authors:  S Iacobelli; P Sismondi; M Giai; M D'Egidio; N Tinari; C Amatetti; P Di Stefano; C Natoli
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.